Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238)-MedSci.cn

Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238)

Weber, J; Mandala, M; Del Vecchio, M; Gogas, H; Arance, AM; Cowey, LC; Dalle, S; Schenker, M; Chiarion-Sileni, V; Marquez-Rodas, I; Grob, JJ; Butler, M; Middleton, MR; Maio, M; Atkinson, V; Queirolo, P; de Pril, V; Qureshi, A; Larkin, J; Ascierto, PA

ANNALS OF ONCOLOGY, 2017; 28 ( ):

科室
- - 订阅+
  - 更多科室
工具
服务